---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-098792"
form_type: "8-K"
ticker: "AIDX"
cik: "0001139685"
company_name: "20/20 Biolabs, Inc."
filed_at: "2026-09-10T20:10:32+00:00"
generated_at: "2026-09-10T20:12:38.861142+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 20/20 Biolabs gets Nasdaq equity non-compliance notice; delisting risk

## Summary
- On Sept 3, 2026, Nasdaq notified 20/20 Biolabs of non-compliance with $2.5M stockholders' equity rule; reported equity $1.62M.
- Company has 45 days to submit compliance plan; if accepted, extension up to 180 days possible.
- Also previously notified July 17, 2026 of bid price non-compliance; must regain $1.00 bid by Jan 13, 2027.
- Failure to cure equity by Jan 13, 2027 would also disqualify additional bid-price cure period.
- Company intends to monitor and consider options to regain compliance.

## SEC filing metadata
- accession: 0001213900-26-098792
- form_type: 8-K
- ticker: AIDX
- cik: 0001139685
- company_name: 20/20 Biolabs, Inc.
- filed_at: 2026-09-10T20:10:32+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1139685/000121390026098792/0001213900-26-098792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1139685/000121390026098792/ea0305119-8k_2020bio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-098792
- JSON: https://secwatch.observer/filing/0001213900-26-098792.json
- Plain text: https://secwatch.observer/filing/0001213900-26-098792.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.